← Product Code [HSX](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX) · K090024 # TGS UNICOMPARTMENTAL KNEE ARTHROPLASTY SYSTEM (K090024) _Alexandria Research Technologies, LLC · HSX · May 4, 2009 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX/K090024 ## Device Facts - **Applicant:** Alexandria Research Technologies, LLC - **Product Code:** [HSX](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX.md) - **Decision Date:** May 4, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3520 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use The TGS Unicompartmental Knee Arthroplasty System is intended for arthroplasty of either condyle of a knee with the following indications: 1. Non-inflammatory degenerative joint disease including post-traumatic arthritis and osteoarthritis. 2. Failed previous implant. 3. Correctable deformity. 4. All TGS® UKA System implants are intended for cemented use only. Components of this system are designed for single use and to be used as a system. ## Device Story TGS® UKA System is a unicompartmental knee prosthesis for femorotibial replacement. System comprises cobalt-chromium femoral components and ultra-high molecular weight polyethylene (UHMWPE) tibial components with radiographic markers. Femoral components available in 6 sizes; tibial components available in 6 sizes, 5 thicknesses, with flat or contoured surfaces, and fixation via contoured pegs or A/P keel. Device used by orthopedic surgeons in clinical settings to replace damaged knee compartments. Components are cemented to bone. System provides mechanical joint surface replacement to restore knee function and alleviate pain associated with degenerative joint disease or failed prior implants. ## Clinical Evidence No clinical data. Substantial equivalence demonstrated through engineering analysis and non-clinical testing. ## Technological Characteristics Materials: Cobalt-chromium alloy (femoral), ultra-high molecular weight polyethylene (tibial). Fixation: Cemented. Features: Radiographic markers, contoured pegs or A/P keel. Design: Unicompartmental femorotibial replacement, 6 sizes, 5 thicknesses, flat or contoured articular surfaces. ## Regulatory Identification A knee joint femorotibial metal/polymer non-constrained cemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits minimally (less than normal anatomic constraints) translation in one or more planes. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral condylar resurfacing component or components made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components made of ultra-high molecular weight polyethylene and are intended for use with bone cement (§ 888.3027). ## Predicate Devices - DePuy Orthopaedics Preservation Unicondylar Knee Prosthesis ([K010810](/device/K010810.md)) - Wright Medical Technology ADVANCE® Unicondylar Knee System ([K012591](/device/K012591.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # K090024 ### 2 510(k) Summary ### Date Prepared: January 2, 2009 ### Submitter's Name / Contact Person ### Manufacturer Alexandria Research Technologics, LLC 13755 First Ave. North, Suite 100 Plymouth, Minnesota 55441 ### Contact Person Mike Renner Vice President Operations Office : 952-949-2235 Fax : 952-949-2007 Email : miker@art-orthopaedics.com ### General Information | Proprietary Name | TGS® Unicompartmental Knee Arthroplasty System (TGS® UKA
System) | |---------------------|----------------------------------------------------------------------------------------------------------| | Common Name | Compartmental Knee Prosthesis System | | Classification Name | CFR 21 888.3520 Knee joint femorotibial metal/polymer non-
constrained cemented prosthesis, Class II | | Classification Name | CFR 21 888.3530 Knee joint femorotibial metal/polymer semi-
constrained cemented prosthesis, Class II | | Product Device Code | HSX, HRY | | Predicate Devices | K010810 DePuy Orthopaedics Preservation Unicondylar Knee
Prosthesis | | Predicate Devices | K012591 Wright Medical Technology ADVANCE® Unicondylar
Knee System | ### Device Description The TGS® UKA System is composed of unicompartmental femoral components and unicompartmental tibial components. These components may be used in various combinations to create a single unicompartmental femorotibial replacement for either the medial or lateral side of the knee. TGS® UK A System components include individually packaged femoral components made of cobalt-chromium allov and all-poly tibial components of ultra-high molecular weight polyethylene with radiographic markers. The femoral components are available in 6 symmetrical sizes for medial or lateral application in right or left knees. The tibial components are available in two sets of 6 sizes; one set for right-medial or leftlateral tibial plateau, and one set for right-lateral or left-medial tibial plateau. Each tibial component size is available in 5 thicknesses with cither flat or contoured articular surface, and with either two contoured pegs or anterior-posterior (A/P) keel cement/bone fixation features. {1}------------------------------------------------ K090024 *2/2 ### Indications for Use The TGS Unicompartmental Knee Arthroplasty System is intended for arthroplasty of either condyle of a knee with the following indications: - 1. Non-inflammatory degenerative joint disease including post-traumatic arthritis and osteoarthritis. - 2. Failed previous implant. - 3. Correctable deformity. - 4. All TGS® UKA System implants are intended for cemented use only. Components of this system are designed for single use and to be used as a system. ### Substantial Equivalence Discussion The indications for use, principles of operation, materials, sizes, type of interface, fixation, packaging, and sterility of the TGS® UKA System components are substantially equivalent to the predicate devices previously cleared for market. The safety and effectiveness of TGS® UKA System are adequately supported by the substantial equivalence information, materials data, and testing results provided within this premarket notification. ### Non-Clinical Testing Engineering analysis was performed to demonstrate that the TGS® UKA System implant components presented no new risks and are substantially equivalent to the predicate devices. ### Clinical Testing Clinical testing was not necessary to demonstrate substantial equivalence between the subject TGS® UKA System implant components and the predicate devices. {2}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" is arranged in a circle around the eagle. The eagle is depicted in black, and the text is also in black. Public Health Service MAY - 4 2009 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Alexandria Research Technologies, LLC % Mr. Michael Renner 13755 First Avenue North, Suite 100 Plymouth, Minnesota 55441 Re: K090024 Trade/Device Name: TGS Unicompartmental Knee Arthroplasty Regulation Number: 21 CFR 888.3520 Regulation Name: Knee joint femorotibial metal/polymer non-constrained cemented prosthesis Regulatory Class: II Product Code: HSX, HRY Dated: April 16, 2009 Received: April 17, 2009 Dear Mr. Renner: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 -CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2 - Mr. Michael Renner If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please contact the CDRH/Office of Surveillance and Biometrics/Division of Postmarket Surveillance at 240-276-3464. For more information regarding the reporting of adverse events, please go to http://www.fda.gov/cdrh/mdr/. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/indcx.html. Sincerely yours, Barbarabonehms Mark N. Melkerson Director Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indications for Use 510(k) Number (if known): K050024 Device Name: TGS® Unicompartmental Knee Arthroplasty System ### Indications for Use: The TGS Unicompartmental Knee Arthroplasty System is intended for arthroplasty of a knee with the following indications: - Non-inflammatory degenerative joint disease including post-traumatic arthritis and osteoarthritis. l. - 2. Failed previous implant. - Correctable deformity 3. - All TGS® UKA System implants are intended for cemented use only. 4. Components of this system are designed for single use and to be used as a system. Prescription Use XX (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Page 1 of 1 · (Posted November 13, 2003) Smita --- (Division Sign. Off) \$ ્દ્રિ . . . icion Sional Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K090024 --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX/K090024](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX/K090024) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com